Rate of increase of plasma drug level influences subjective response in humans.
about
E-cigarettes--prevention, pulmonary health, and addictionFamilial aggregation of tobacco use behaviors among Amish men.Can you vaccinate against substance abuse?Modafinil-induced conditioned place preference via dopaminergic system in mice.Attenuation of cocaine-induced locomotor activity in male and female mice by active immunization.Are adolescents more vulnerable to drug addiction than adults? Evidence from animal modelsInhalation of Alcohol Vapor: Measurement and Implications.Nicotine Absorption from Smokeless Tobacco Modified to Adjust pH.Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential.Rapid delivery of cocaine facilitates acquisition of self-administration in rats: an effect masked by paired stimuliNicotine related brain activity: the influence of smoking history and blood nicotine levels, an exploratory study.Increasing the incentive salience of cocaine challenges preference for pup- over cocaine-associated stimuli during early postpartum: place preference and locomotor analyses in the lactating female rat.Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusersAnti-(+)-methamphetamine monoclonal antibody antagonists designed to prevent the progression of human diseases of addictionAssessment of a formulation designed to be crush-resistant in prescription opioid abusers.The rate of intravenous cocaine or amphetamine delivery does not influence drug-taking and drug-seeking behavior in ratsA Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of OxycodoneThe relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers.A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats.Can abuse deterrent formulations make a difference? Expectation and speculation.Genetic and pharmacokinetic determinants of response to transdermal nicotine in white, black, and Asian nonsmokersThe effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER).A systematic review of nicotine by inhalation: is there a role for the inhaled route?Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets in healthy nondependent recreational users of prescription opioids: a randomized trial.Nicotine: abused substance and therapeutic agent.Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid UsersThinking outside the synapse: pharmacokinetic-based medications for cocaine addiction.Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone.Relative Bioavailability, Intranasal Abuse Potential, and Safety of Benzhydrocodone/Acetaminophen Compared with Hydrocodone Bitartrate/Acetaminophen in Recreational Drug Abusers.Altered methamphetamine place conditioning in mice vaccinated with a succinyl-methamphetamine-tetanus-toxoid vaccine.Self-administration of intravenous nicotine in male and female cigarette smokers.Importance of Pharmacokinetic Profile and Timing of Coadministration of Short– and Long–Acting Formulations of Methylphenidate on Patterns of Subjective Responses and Abuse Potential
P2860
Q28241022-1CD7F013-DBB7-4F76-A448-73546D5FAD76Q33813151-25E267CE-AF26-41FA-A4BD-33EC680C8D43Q34132788-4210F5EE-F862-49E4-89D3-ACFA81242AD9Q34154970-3A4783CE-CA5E-4240-AAE6-A623485DD990Q34287658-C926CDD5-8851-4A04-8D01-AC7C6AFE8B74Q34513218-F49986E6-0F13-442C-B078-0C89FB26797AQ34548568-4F8D820C-1656-45AF-8BDD-BEC9320E4920Q34738475-1843CB79-4470-417E-B049-DF5C48525C57Q35079452-6A46EAE7-8521-4673-84A6-24FABC18A82AQ35085890-CDCCD720-2058-4C54-9FC4-CF0458C22261Q36640128-5714B2F1-6DED-4C65-AE4F-2F03FD000B0BQ36731516-6BA2580C-DC37-40BE-905B-FB96D0B6A36DQ36803326-6E9DBA94-9988-41A5-95B6-003D4E4F7D15Q36838980-DE739531-C1A7-441E-A804-4C44FD9374BEQ36845718-A238A106-DD4E-465A-904B-8028877957F2Q36957664-FE0CA410-FCEC-4C00-81E6-0AB175BF2C7EQ36972164-A8F58242-682B-4286-A6B5-5F29E822CCC0Q37156564-71CE3164-E59E-4014-8EA2-A86465DE3BE9Q37172159-E7B4514D-8A85-45E5-90B1-03F5B149E5C7Q37223480-F9C9FD2D-57BA-44EC-87B5-0AED046B155EQ37325457-B4D44BDA-633B-446A-AAA2-58EEA9DD2F7FQ37404465-931AA9DB-16CF-4BAA-B147-858128D3A1BCQ37717944-8E59A1D3-872F-4D68-8DEB-8D9F637D87FCQ37989379-F0684EB3-7343-4E4D-B8C4-541AB6074919Q38241632-BFBBE086-E071-4DD3-A14D-02BF6910FACFQ41741650-75DEC6F7-1AD6-4F22-84FF-CDF1DE8CEE34Q42357273-9081C27B-21FE-4724-9523-77CB9DBC83B7Q42577570-C86F211E-DE80-4E9E-B71C-4B409E3AEBF8Q44340250-92187218-F379-4BCE-85AD-CD0A26B31D51Q44344331-284BC9ED-12F1-4B29-8E8B-45306B79C955Q50100164-4FDACD0D-AAFC-4840-876E-1A009B3FF82CQ50548841-EE161B85-6047-42A2-B3AE-EF6C9DE097A0Q51751824-3AE7D8EB-8C2D-4EDF-984E-AF4C4A792274Q57399801-42D6E468-05B6-4285-9A66-7AE22C48FF8A
P2860
Rate of increase of plasma drug level influences subjective response in humans.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Rate of increase of plasma drug level influences subjective response in humans.
@en
Rate of increase of plasma drug level influences subjective response in humans.
@nl
type
label
Rate of increase of plasma drug level influences subjective response in humans.
@en
Rate of increase of plasma drug level influences subjective response in humans.
@nl
prefLabel
Rate of increase of plasma drug level influences subjective response in humans.
@en
Rate of increase of plasma drug level influences subjective response in humans.
@nl
P2860
P356
P1433
P1476
Rate of increase of plasma drug level influences subjective response in humans.
@en
P2093
P2860
P2888
P304
P356
10.1007/BF02245161
P577
1992-01-01T00:00:00Z